Differences in Uptravi maintenance doses had no impact on the risk of hospitalization among adults with PAH, a claims ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented ...

We recently published a list of 16 Best Mid Cap Growth Stocks To Buy Now. In this article, we are going to take a look at ...

In The Lancet Respiratory Medicine, Olivier Sitbon and colleagues1 present the results of a randomised, phase 2b clinical trial (ELEVATE-2) that compared the safety and efficacy of pulmonary arterial ...

Investigators say more research is warranted to optimize management of patients with pulmonary arterial hypertension (PAH) ...

They also produce signaling molecules like nitric oxide and prostacyclin to maintain vascular balance. However, EC ...

Most participants were receiving either three (61%) or two (35%) background drugs for PAH, and 40% were receiving prostacyclin infusions. The mean time from PAH diagnosis was 8.8 years.

Most participants were receiving either three (61%) or two (35%) background drugs for PAH, and 40% were receiving prostacyclin infusions. The mean time from PAH diagnosis was 8.8 years. Patients had a ...

The key targets in the Raynauds Disease pipeline products market include Prostaglandin E2 Receptor EP1 Subtype (Prostanoid EP1 Receptor or PTGER1), Prostaglandin E Synthase (Microsomal Glutathione S ...

Future Cardiol. 2013;9(3):335-349. Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited, likely due to the early termination of the FIRST trial. [55] This study ...